Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 223 entries
Sorted by: Best Match Show Resources per page
14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts.

Breast care (Basel, Switzerland)

Jackisch C, Harbeck N, Huober J, von Minckwitz G, Gerber B, Kreipe HH, Liedtke C, Marschner N, Möbus V, Scheithauer H, Schneeweiss A, Thomssen C, Loibl S, Beckmann MW, Blohmer JU, Costa SD, Decker T, Diel I, Fasching PA, Fehm T, Janni W, Lück HJ, Maass N, Scharl A, Untch M.
PMID: 26557827
Breast Care (Basel). 2015 Jul;10(3):211-9. doi: 10.1159/000433590. Epub 2015 Jun 23.

The key topics of this year's 14th St. Gallen Consensus Conference on the diagnosis and therapy of primary breast cancer were again questions about breast surgery and axillary surgery, radio-oncology and systemic therapy options in consideration of tumor biology,...

Cite
Jackisch C, Harbeck N, Huober J, et al. 14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts. Breast Care (Basel). 2015;10(3):211-9doi: 10.1159/000433590.
Jackisch, C., Harbeck, N., Huober, J., von Minckwitz, G., Gerber, B., Kreipe, H. H., Liedtke, C., Marschner, N., Möbus, V., Scheithauer, H., Schneeweiss, A., Thomssen, C., Loibl, S., Beckmann, M. W., Blohmer, J. U., Costa, S. D., Decker, T., Diel, I., Fasching, P. A., Fehm, T., Janni, W., Lück, H. J., Maass, N., Scharl, A., & Untch, M. (2015). 14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts. Breast care (Basel, Switzerland), 10(3), 211-9. https://doi.org/10.1159/000433590
Jackisch, Christian, et al. "14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts." Breast care (Basel, Switzerland) vol. 10,3 (2015): 211-9. doi: https://doi.org/10.1159/000433590
Jackisch C, Harbeck N, Huober J, von Minckwitz G, Gerber B, Kreipe HH, Liedtke C, Marschner N, Möbus V, Scheithauer H, Schneeweiss A, Thomssen C, Loibl S, Beckmann MW, Blohmer JU, Costa SD, Decker T, Diel I, Fasching PA, Fehm T, Janni W, Lück HJ, Maass N, Scharl A, Untch M. 14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts. Breast Care (Basel). 2015 Jul;10(3):211-9. doi: 10.1159/000433590. Epub 2015 Jun 23. PMID: 26557827; PMCID: PMC4569213.
Copy Download .nbib Format: NLM
Progesterone receptor membrane component 1 is phosphorylated upon progestin treatment in breast cancer cells.

Oncotarget

Willibald M, Bayer G, Stahlhut V, Poschmann G, Stühler K, Gierke B, Pawlak M, Seeger H, Mueck AO, Niederacher D, Fehm T, Neubauer H.
PMID: 29069804
Oncotarget. 2017 Aug 02;8(42):72480-72493. doi: 10.18632/oncotarget.19819. eCollection 2017 Sep 22.

Menopausal hormone therapy, using estrogen and synthetic progestins, is associated with an increased risk of developing breast cancer. The effect of progestins on breast cells is complex and not yet fully understood. In previous

Cite
Willibald M, Bayer G, Stahlhut V, et al. Progesterone receptor membrane component 1 is phosphorylated upon progestin treatment in breast cancer cells. Oncotarget. 2017;8(42):72480-72493doi: 10.18632/oncotarget.19819.
Willibald, M., Bayer, G., Stahlhut, V., Poschmann, G., Stühler, K., Gierke, B., Pawlak, M., Seeger, H., Mueck, A. O., Niederacher, D., Fehm, T., & Neubauer, H. (2017). Progesterone receptor membrane component 1 is phosphorylated upon progestin treatment in breast cancer cells. Oncotarget, 8(42), 72480-72493. https://doi.org/10.18632/oncotarget.19819
Willibald, Marina, et al. "Progesterone receptor membrane component 1 is phosphorylated upon progestin treatment in breast cancer cells." Oncotarget vol. 8,42 (2017): 72480-72493. doi: https://doi.org/10.18632/oncotarget.19819
Willibald M, Bayer G, Stahlhut V, Poschmann G, Stühler K, Gierke B, Pawlak M, Seeger H, Mueck AO, Niederacher D, Fehm T, Neubauer H. Progesterone receptor membrane component 1 is phosphorylated upon progestin treatment in breast cancer cells. Oncotarget. 2017 Aug 02;8(42):72480-72493. doi: 10.18632/oncotarget.19819. eCollection 2017 Sep 22. PMID: 29069804; PMCID: PMC5641147.
Copy Download .nbib Format: NLM
Clinical validation of genetic variants associated with .

Oncotarget

Fasching PA, Häberle L, Rack B, Li L, Hein A, Ekici AB, Reis A, Lux MP, Cunningham JM, Ruebner M, Jenkins G, Fridley B, Schneeweiss A, Tesch H, Lichtenegger W, Fehm T, Heinrich G, Rezai M, Beckmann MW, Janni W, Weinshilboum RM, Wang L.
PMID: 29100455
Oncotarget. 2017 May 09;8(44):78133-78143. doi: 10.18632/oncotarget.17726. eCollection 2017 Sep 29.

Hematotoxicity is one of the major side effects of chemotherapy. The aim of this study was to examine the association between single nucleotide polymorphisms (SNPs) and hematotoxicity in breast cancer patients in a subset of patients of the SUCCESS...

Cite
Fasching PA, Häberle L, Rack B, et al. Clinical validation of genetic variants associated with . Oncotarget. 2017;8(44):78133-78143doi: 10.18632/oncotarget.17726.
Fasching, P. A., Häberle, L., Rack, B., Li, L., Hein, A., Ekici, A. B., Reis, A., Lux, M. P., Cunningham, J. M., Ruebner, M., Jenkins, G., Fridley, B., Schneeweiss, A., Tesch, H., Lichtenegger, W., Fehm, T., Heinrich, G., Rezai, M., Beckmann, M. W., Janni, W., Weinshilboum, R. M., & Wang, L. (2017). Clinical validation of genetic variants associated with . Oncotarget, 8(44), 78133-78143. https://doi.org/10.18632/oncotarget.17726
Fasching, Peter A, et al. "Clinical validation of genetic variants associated with ." Oncotarget vol. 8,44 (2017): 78133-78143. doi: https://doi.org/10.18632/oncotarget.17726
Fasching PA, Häberle L, Rack B, Li L, Hein A, Ekici AB, Reis A, Lux MP, Cunningham JM, Ruebner M, Jenkins G, Fridley B, Schneeweiss A, Tesch H, Lichtenegger W, Fehm T, Heinrich G, Rezai M, Beckmann MW, Janni W, Weinshilboum RM, Wang L. Clinical validation of genetic variants associated with . Oncotarget. 2017 May 09;8(44):78133-78143. doi: 10.18632/oncotarget.17726. eCollection 2017 Sep 29. PMID: 29100455; PMCID: PMC5652844.
Copy Download .nbib Format: NLM
Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention.

Geburtshilfe und Frauenheilkunde

Schneeweiss A, Lux MP, Janni W, Hartkopf AD, Nabieva N, Taran FA, Overkamp F, Kolberg HC, Hadji P, Tesch H, Wöckel A, Ettl J, Lüftner D, Wallwiener M, Müller V, Beckmann MW, Belleville E, Wallwiener D, Brucker SY, Schütz F, Fasching PA, Fehm TN.
PMID: 29576630
Geburtshilfe Frauenheilkd. 2018 Mar;78(3):246-259. doi: 10.1055/s-0044-101614. Epub 2018 Mar 21.

The treatment of metastatic breast cancer has become more complicated due to increasing numbers of new therapies which need to be tested. Therapies are now being developed to treat special clinical or molecular subgroups. Even though intrinsic molecular subtypes...

Cite
Schneeweiss A, Lux MP, Janni W, et al. Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention. Geburtshilfe Frauenheilkd. 2018;78(3):246-259doi: 10.1055/s-0044-101614.
Schneeweiss, A., Lux, M. P., Janni, W., Hartkopf, A. D., Nabieva, N., Taran, F. A., Overkamp, F., Kolberg, H. C., Hadji, P., Tesch, H., Wöckel, A., Ettl, J., Lüftner, D., Wallwiener, M., Müller, V., Beckmann, M. W., Belleville, E., Wallwiener, D., Brucker, S. Y., Schütz, F., Fasching, P. A., & Fehm, T. N. (2018). Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention. Geburtshilfe und Frauenheilkunde, 78(3), 246-259. https://doi.org/10.1055/s-0044-101614
Schneeweiss, Andreas, et al. "Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention." Geburtshilfe und Frauenheilkunde vol. 78,3 (2018): 246-259. doi: https://doi.org/10.1055/s-0044-101614
Schneeweiss A, Lux MP, Janni W, Hartkopf AD, Nabieva N, Taran FA, Overkamp F, Kolberg HC, Hadji P, Tesch H, Wöckel A, Ettl J, Lüftner D, Wallwiener M, Müller V, Beckmann MW, Belleville E, Wallwiener D, Brucker SY, Schütz F, Fasching PA, Fehm TN. Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention. Geburtshilfe Frauenheilkd. 2018 Mar;78(3):246-259. doi: 10.1055/s-0044-101614. Epub 2018 Mar 21. PMID: 29576630; PMCID: PMC5862553.
Copy Download .nbib Format: NLM
Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM Study.

Geburtshilfe und Frauenheilkunde

Fasching PA, Fehm T, Kellner S, de Waal J, Rezai M, Baier B, Baake G, Kolberg HC, Guggenberger M, Warm M, Harbeck N, Würstlein R, Deuker JU, Dall P, Richter B, Wachsmann G, Brucker C, Siebers JW, Fersis N, Kuhn T, Wolf C, Vollert HW, Breitbach GP, Janni W, Landthaler R, Kohls A, Rezek D, Noesslet T, Fischer G, Henschen S, Praetz T, Heyl V, Kühn T, Krauß T, Thomssen C, Kümmel S, Hohn A, Tesch H, Mundhenke C, Hein A, Rauh C, Bayer CM, Jacob A, Schmidt K, Belleville E, Hadji P, Wallwiener D, Grischke EM, Beckmann MW, Brucker SY.
PMID: 25568468
Geburtshilfe Frauenheilkd. 2014 Dec;74(12):1137-1143. doi: 10.1055/s-0034-1383401.

No abstract available.

Cite
Fasching PA, Fehm T, Kellner S, et al. Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM Study. Geburtshilfe Frauenheilkd. 2014;74(12):1137-1143doi: 10.1055/s-0034-1383401.
Fasching, P. A., Fehm, T., Kellner, S., de Waal, J., Rezai, M., Baier, B., Baake, G., Kolberg, H. C., Guggenberger, M., Warm, M., Harbeck, N., Würstlein, R., Deuker, J. U., Dall, P., Richter, B., Wachsmann, G., Brucker, C., Siebers, J. W., Fersis, N., Kuhn, T., Wolf, C., Vollert, H. W., Breitbach, G. P., Janni, W., Landthaler, R., Kohls, A., Rezek, D., Noesslet, T., Fischer, G., Henschen, S., Praetz, T., Heyl, V., Kühn, T., Krauß, T., Thomssen, C., Kümmel, S., Hohn, A., Tesch, H., Mundhenke, C., Hein, A., Rauh, C., Bayer, C. M., Jacob, A., Schmidt, K., Belleville, E., Hadji, P., Wallwiener, D., Grischke, E. M., Beckmann, M. W., & Brucker, S. Y. (2014). Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM Study. Geburtshilfe und Frauenheilkunde, 74(12), 1137-1143. https://doi.org/10.1055/s-0034-1383401
Fasching, P A, et al. "Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM Study." Geburtshilfe und Frauenheilkunde vol. 74,12 (2014): 1137-1143. doi: https://doi.org/10.1055/s-0034-1383401
Fasching PA, Fehm T, Kellner S, de Waal J, Rezai M, Baier B, Baake G, Kolberg HC, Guggenberger M, Warm M, Harbeck N, Würstlein R, Deuker JU, Dall P, Richter B, Wachsmann G, Brucker C, Siebers JW, Fersis N, Kuhn T, Wolf C, Vollert HW, Breitbach GP, Janni W, Landthaler R, Kohls A, Rezek D, Noesslet T, Fischer G, Henschen S, Praetz T, Heyl V, Kühn T, Krauß T, Thomssen C, Kümmel S, Hohn A, Tesch H, Mundhenke C, Hein A, Rauh C, Bayer CM, Jacob A, Schmidt K, Belleville E, Hadji P, Wallwiener D, Grischke EM, Beckmann MW, Brucker SY. Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM Study. Geburtshilfe Frauenheilkd. 2014 Dec;74(12):1137-1143. doi: 10.1055/s-0034-1383401. PMID: 25568468; PMCID: PMC4275317.
Copy Download .nbib Format: NLM
Pathway Oriented Therapy in Breast Cancer - a Light at the End of the Tunnel!.

Breast care (Basel, Switzerland)

Ruckhäberle E, Fehm T.
PMID: 28228703
Breast Care (Basel). 2016 Dec;11(6):382-383. doi: 10.1159/000454659. Epub 2016 Dec 08.

No abstract available.

Cite
Ruckhäberle E, Fehm T. Pathway Oriented Therapy in Breast Cancer - a Light at the End of the Tunnel!. Breast Care (Basel). 2016;11(6):382-383doi: 10.1159/000454659.
Ruckhäberle, E., & Fehm, T. (2016). Pathway Oriented Therapy in Breast Cancer - a Light at the End of the Tunnel!. Breast care (Basel, Switzerland), 11(6), 382-383. https://doi.org/10.1159/000454659
Ruckhäberle, Eugen, and Fehm, Tanja. "Pathway Oriented Therapy in Breast Cancer - a Light at the End of the Tunnel!." Breast care (Basel, Switzerland) vol. 11,6 (2016): 382-383. doi: https://doi.org/10.1159/000454659
Ruckhäberle E, Fehm T. Pathway Oriented Therapy in Breast Cancer - a Light at the End of the Tunnel!. Breast Care (Basel). 2016 Dec;11(6):382-383. doi: 10.1159/000454659. Epub 2016 Dec 08. PMID: 28228703; PMCID: PMC5290442.
Copy Download .nbib Format: NLM
New insight on a possible mechanism of progestogens in terms of breast cancer risk.

Hormone molecular biology and clinical investigation

Neubauer H, Chen R, Schneck H, Knorrp T, Templin MF, Fehm T, Cahill MA, Seeger H, Yu Q, Mueck AO.
PMID: 25961254
Horm Mol Biol Clin Investig. 2011 Apr 01;6(1):185-92. doi: 10.1515/HMBCI.2010.082.

OBJECTIVES: Progestogens influence mammary gland development and probably breast cancer tumorigenesis by regulating a broad spectrum of physiological processes. We investigated receptor membrane-initiated actions of progestogens in MCF-7 breast cancer cells overexpressing progesterone receptor membrane component 1 (PGRMC1).DESIGN: MCF-7...

Cite
Neubauer H, Chen R, Schneck H, et al. New insight on a possible mechanism of progestogens in terms of breast cancer risk. Horm Mol Biol Clin Investig. 2011;6(1):185-92doi: 10.1515/HMBCI.2010.082.
Neubauer, H., Chen, R., Schneck, H., Knorrp, T., Templin, M. F., Fehm, T., Cahill, M. A., Seeger, H., Yu, Q., & Mueck, A. O. (2011). New insight on a possible mechanism of progestogens in terms of breast cancer risk. Hormone molecular biology and clinical investigation, 6(1), 185-92. https://doi.org/10.1515/HMBCI.2010.082
Neubauer, Hans, et al. "New insight on a possible mechanism of progestogens in terms of breast cancer risk." Hormone molecular biology and clinical investigation vol. 6,1 (2011): 185-92. doi: https://doi.org/10.1515/HMBCI.2010.082
Neubauer H, Chen R, Schneck H, Knorrp T, Templin MF, Fehm T, Cahill MA, Seeger H, Yu Q, Mueck AO. New insight on a possible mechanism of progestogens in terms of breast cancer risk. Horm Mol Biol Clin Investig. 2011 Apr 01;6(1):185-92. doi: 10.1515/HMBCI.2010.082. PMID: 25961254.
Copy Download .nbib Format: NLM
Monitoring in metastatic breast cancer: is imaging outdated in the era of circulating tumor cells?.

Breast care (Basel, Switzerland)

Alunni-Fabbroni M, Müller V, Fehm T, Janni W, Rack B.
PMID: 24803882
Breast Care (Basel). 2014 Feb;9(1):16-21. doi: 10.1159/000360438.

In clinical practice imaging technologies such as computed tomography (CT), positron emission tomography (PET)/CT and magnetic resonance imaging (MRI) are well-established methods for monitoring metastatic breast cancer (MBC) patients and for assessing therapeutic efficacy. However, several weeks of treatment...

Cite
Alunni-Fabbroni M, Müller V, Fehm T, et al. Monitoring in metastatic breast cancer: is imaging outdated in the era of circulating tumor cells?. Breast Care (Basel). 2014;9(1):16-21doi: 10.1159/000360438.
Alunni-Fabbroni, M., Müller, V., Fehm, T., Janni, W., & Rack, B. (2014). Monitoring in metastatic breast cancer: is imaging outdated in the era of circulating tumor cells?. Breast care (Basel, Switzerland), 9(1), 16-21. https://doi.org/10.1159/000360438
Alunni-Fabbroni, Marianna, et al. "Monitoring in metastatic breast cancer: is imaging outdated in the era of circulating tumor cells?." Breast care (Basel, Switzerland) vol. 9,1 (2014): 16-21. doi: https://doi.org/10.1159/000360438
Alunni-Fabbroni M, Müller V, Fehm T, Janni W, Rack B. Monitoring in metastatic breast cancer: is imaging outdated in the era of circulating tumor cells?. Breast Care (Basel). 2014 Feb;9(1):16-21. doi: 10.1159/000360438. PMID: 24803882; PMCID: PMC3995372.
Copy Download .nbib Format: NLM
[The functional relation between the gut and the liver: the newly discovered hormone relm-beta affects the action of insulin].

Zeitschrift fur Gastroenterologie

Fehmann HC.
PMID: 14562201
Z Gastroenterol. 2003 Oct;41(10):1033-4. doi: 10.1055/s-2003-42925.

No abstract available.

Cite
Fehmann HC. Die funktionelle Verbindung zwischen Darm und Leber: Das neu entdeckte Hormon RELM-Beta beeinflusst die Insulinwirkung. [The functional relation between the gut and the liver: the newly discovered hormone relm-beta affects the action of insulin]. Z Gastroenterol. 2003;41(10):1033-4doi: 10.1055/s-2003-42925.
Fehmann, H. C. (2003). Die funktionelle Verbindung zwischen Darm und Leber: Das neu entdeckte Hormon RELM-Beta beeinflusst die Insulinwirkung. [The functional relation between the gut and the liver: the newly discovered hormone relm-beta affects the action of insulin]. Zeitschrift fur Gastroenterologie, 41(10), 1033-4. https://doi.org/10.1055/s-2003-42925
Fehmann, H C. "Die funktionelle Verbindung zwischen Darm und Leber: Das neu entdeckte Hormon RELM-Beta beeinflusst die Insulinwirkung." [The functional relation between the gut and the liver: the newly discovered hormone relm-beta affects the action of insulin]. Zeitschrift fur Gastroenterologie vol. 41,10 (2003): 1033-4. doi: https://doi.org/10.1055/s-2003-42925
Fehmann HC. Die funktionelle Verbindung zwischen Darm und Leber: Das neu entdeckte Hormon RELM-Beta beeinflusst die Insulinwirkung. [The functional relation between the gut and the liver: the newly discovered hormone relm-beta affects the action of insulin]. Z Gastroenterol. 2003 Oct;41(10):1033-4. doi: 10.1055/s-2003-42925. German. PMID: 14562201.
Copy Download .nbib Format: NLM
Marangoni flow: an additional mechanism in boiling heat transfer.

Science (New York, N.Y.)

McGrew JL, Bamford FL, Rehm TR.
PMID: 17737589
Science. 1966 Sep 02;153(3740):1106-7. doi: 10.1126/science.153.3740.1106.

Experimental results indicate that extensive liquid circulation can be established by surface tension gradients near bubbles attached to heated surfaces. This circulation can contribute significantly to the high rate of heat transfer observed under boiling conditions.

Cite
McGrew JL, Bamford FL, Rehm TR. Marangoni flow: an additional mechanism in boiling heat transfer. Science. 1966;153(3740):1106-7doi: 10.1126/science.153.3740.1106.
McGrew, J. L., Bamford, F. L., & Rehm, T. R. (1966). Marangoni flow: an additional mechanism in boiling heat transfer. Science (New York, N.Y.), 153(3740), 1106-7. https://doi.org/10.1126/science.153.3740.1106
McGrew, J L, et al. "Marangoni flow: an additional mechanism in boiling heat transfer." Science (New York, N.Y.) vol. 153,3740 (1966): 1106-7. doi: https://doi.org/10.1126/science.153.3740.1106
McGrew JL, Bamford FL, Rehm TR. Marangoni flow: an additional mechanism in boiling heat transfer. Science. 1966 Sep 02;153(3740):1106-7. doi: 10.1126/science.153.3740.1106. PMID: 17737589.
Copy Download .nbib Format: NLM
Insulinotropic glucagonlike peptide-I(7-37)/(7-36)amide A new incretin hormone.

Trends in endocrinology and metabolism: TEM

Fehmann HC, Habener JF.
PMID: 18407095
Trends Endocrinol Metab. 1992 Jul;3(5):158-63. doi: 10.1016/1043-2760(92)90165-w.

Intestinal peptide hormones, released into circulation in response to a meal, are important augmentors of the postprandial insulin release stimulated by absorbed nutrients. In this "Incretin concept" glucagon-like peptide I(7-37) plays a major role because it is the most...

Cite
Fehmann HC, Habener JF. Insulinotropic glucagonlike peptide-I(7-37)/(7-36)amide A new incretin hormone. Trends Endocrinol Metab. 1992;3(5):158-63doi: 10.1016/1043-2760(92)90165-w.
Fehmann, H. C., & Habener, J. F. (1992). Insulinotropic glucagonlike peptide-I(7-37)/(7-36)amide A new incretin hormone. Trends in endocrinology and metabolism: TEM, 3(5), 158-63. https://doi.org/10.1016/1043-2760(92)90165-w
Fehmann, H C, and Habener, J F. "Insulinotropic glucagonlike peptide-I(7-37)/(7-36)amide A new incretin hormone." Trends in endocrinology and metabolism: TEM vol. 3,5 (1992): 158-63. doi: https://doi.org/10.1016/1043-2760(92)90165-w
Fehmann HC, Habener JF. Insulinotropic glucagonlike peptide-I(7-37)/(7-36)amide A new incretin hormone. Trends Endocrinol Metab. 1992 Jul;3(5):158-63. doi: 10.1016/1043-2760(92)90165-w. PMID: 18407095.
Copy Download .nbib Format: NLM
New Developments in Breast Cancer Therapy Presented at ASCO 2010.

Breast care (Basel, Switzerland)

Müllera V, Dubsky P, Fehm T, Fitzal F, Huober J, Schmidt M, Steger G.
PMID: 22590448
Breast Care (Basel). 2010 Aug;5(4):266-271. doi: 10.1159/000319583. Epub 2010 Aug 09.

No abstract available.

Cite
Müllera V, Dubsky P, Fehm T, et al. New Developments in Breast Cancer Therapy Presented at ASCO 2010. Breast Care (Basel). 2010;5(4):266-271doi: 10.1159/000319583.
Müllera, V., Dubsky, P., Fehm, T., Fitzal, F., Huober, J., Schmidt, M., & Steger, G. (2010). New Developments in Breast Cancer Therapy Presented at ASCO 2010. Breast care (Basel, Switzerland), 5(4), 266-271. https://doi.org/10.1159/000319583
Müllera, Volkmar, et al. "New Developments in Breast Cancer Therapy Presented at ASCO 2010." Breast care (Basel, Switzerland) vol. 5,4 (2010): 266-271. doi: https://doi.org/10.1159/000319583
Müllera V, Dubsky P, Fehm T, Fitzal F, Huober J, Schmidt M, Steger G. New Developments in Breast Cancer Therapy Presented at ASCO 2010. Breast Care (Basel). 2010 Aug;5(4):266-271. doi: 10.1159/000319583. Epub 2010 Aug 09. PMID: 22590448; PMCID: PMC3346173.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 223 entries